Matthew J Olnes

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
  2. pmc Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors
    Matthew J Olnes
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 52:537-41. 2012
  3. doi request reprint Targeting immune dysregulation in myelodysplastic syndromes
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, and Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bldg 10 CRC 3 1341, Bethesda, MD 20892, USA
    JAMA 305:814-9. 2011
  4. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
  5. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
  6. doi request reprint Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
    Ankur R Parikh
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Semin Hematol 49:304-11. 2012
  7. pmc Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
    Elaine M Sloand
    National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
    Haematologica 95:382-7. 2010
  8. pmc Eltrombopag and improved hematopoiesis in refractory aplastic anemia
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 367:11-9. 2012

Detail Information

Publications8

  1. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
    ..Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS...
  2. pmc Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors
    Matthew J Olnes
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 52:537-41. 2012
    ..However, there are no studies addressing whether repeated administration of G-CSF produces Monosomy 7 aneuploidy in healthy donors...
  3. doi request reprint Targeting immune dysregulation in myelodysplastic syndromes
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, and Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bldg 10 CRC 3 1341, Bethesda, MD 20892, USA
    JAMA 305:814-9. 2011
    ..In this article, we review the pathobiology of immune dysregulation in MDS and summarize the role of immunosuppressive therapy in MDS...
  4. pmc Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
    J Clin Oncol 28:5166-73. 2010
    ..Because of the toxicities associated with h-ATG/CsA, we investigated an alternative regimen with alemtuzumab in MDS...
  5. pmc T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
    Elaine M Sloand
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 117:2691-9. 2011
    ..Thus, our results suggest that WT1 is one of the antigens that triggers T cell-mediated myelosuppression in MDS...
  6. doi request reprint Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
    Ankur R Parikh
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Semin Hematol 49:304-11. 2012
    ....
  7. pmc Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab
    Elaine M Sloand
    National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
    Haematologica 95:382-7. 2010
    ....
  8. pmc Eltrombopag and improved hematopoiesis in refractory aplastic anemia
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 367:11-9. 2012
    ..Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells...